@entity788 , XXXX , and pregnancy.

@entity2298 @entity1 @entity788 @entity3747 @entity407 @entity548 @entity231 @entity14755 @entity412 @entity42000 @entity9007 @entity30176 @entity3295 @entity165
Interrelationships between pregnancy, @entity2298 , and @entity788 were assessed in three @entity1 with @entity3295 . One subject had known @entity3295 , @entity30176 , prior to conception. In this @entity1 a progressive increase in @entity412 levels to more than 3,000 mg/dl during the first two trimesters required dietary intervention and hospitalization at 28 weeks' gestation. Use of an isocaloric National Institutes of Health type V diet reduced @entity412 levels to less than 900 mg/dl; the pregnancy was uneventful with term delivery of a healthy neonate. The @entity3295 was covert in the other two @entity1 until term. In one subject, subsequently shown to have @entity14755 , @entity548 with a @entity9007 , and @entity3747 developed at 39 weeks' gestation; the neonate was safely delivered, and the mother survived. In the second, entirely asymptomatic subject, @entity412 levels greater than 5,000 mg/dl were discovered incidentally at term cesarean section during delivery of a healthy neonate. With a fat restricted diet, plasma @entity412 levels abruptly fell post partum to less than 500 mg/dl, and subsequent studies revealed @entity42000 . Routine quantitation of plasma @entity165 and @entity412 levels or simple visual examination of fasting plasma for @entity412 -induced @entity231 or "milky" appearance should be done during early pregnancy. This would allow the obstetrician to identify @entity1 with severe @entity3295 prior to the superimposition of the physiologic @entity407 of pregnancy upon @entity3295 with resultant, and often catastrophic, acute @entity788 .
